natgillin/translations-raw huggingface dataset:
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Pelzont to the woman. 
Odločiti se je treba med nadaljevanjem/prenehanjem dojenja in nadaljevanjem/prenehanjem zdravljenja, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja z zdravilom Pelzont za mater.
• increased blood pressure 
• zvišan krvni tlak
If you have these symptoms talk to your doctor immediately. 
Če imate katerega od teh simptomov, se takoj posvetujte z zdravnikom.
Though total mortality was similar in the two groups at five years, in a fifteen-year cumulative follow-up there were 11 % fewer deaths in the nicotinic acid group compared to the placebo cohort. 
Po petih letih je bila sicer celotna umrljivost v obeh skupinah podobna, a med petnajstletnim kumulativnim spremljanjem so v skupini, ki je dobivala nikotinsko kislino, ugotovili 11 % manj smrti kot v kohorti s placebom.
Northumberland NE23 3JU United Kingdom 
Northumberland NE23 3JU Velika Britanija
If these levels are found, in the absence of strenuous exercise, to be significantly elevated (> 5 x ULN), treatment should be stopped. 
Če je pri bolniku, ki redno ne trenira, ta raven pomembno zvišana (> 5 x ZMN), je treba zdravljenje prekiniti.
• skin disorder with dark velvety plaques called acanthosis nigricans 
• bolezen kože s temnimi, žametastimi lehami, ki se imenuje acanthosis nigricans
• After 4 weeks, your doctor may raise your dose to two tablets a day. 
• Po 4 tednih vam zdravnik lahko odmerek poveča na dve tableti na dan.
• Arterial bleeding. 
• Arterijska krvavitev.
Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom 
Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon Hertfordshire EN11 9BU Velika Britanija
Pelzont is used in addition to diet 
Zdravilo Pelzont se uporablja poleg diete za:
Animal studies have shown excretion of laropiprant in milk. 
Študije na živalih so pokazale, da se laropiprant izloča v mleko.
Safety and effectiveness of Pelzont in paediatric patients under the age of 18 years have not been established. 
Pediatrična populacija Varnost in učinkovitost zdravila Pelzont pri pediatričnih bolnikih, mlajših od 18 let, nista bili dokazani.
Laropiprant also has affinity for the thromboxane A2 receptor (TP) (although it is substantially less potent at TP as compared to DP1). 
Laropiprant ima tudi afiniteto za receptor (TP) za tromboksan A2 (čeprav je za TP veliko manj močna kot za DP1).
Treatment with nicotinic acid reduces the risk of death and cardiovascular events, and slows progression or promotes regression of atherosclerotic lesions. 
Zdravljenje z nikotinsko kislino zmanjšuje tveganje za smrt in srčno-žilne dogodke ter upočasni napredovanje ali pripomore k nazadovanju aterosklerotičnih sprememb.
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
• Preobčutljivost na zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1.
Therefore, Pelzont should not be used during pregnancy unless clearly necessary. 
Zato se zdravila Pelzont ne sme uporabljati pri nosečnicah, razen če to ni nujno.
If you take aspirin for any other reason, continue to follow your doctor's advice. 
Če jemljete acetilsalicilno kislino zaradi drugih vzrokov, še naprej upoštevajte navodila zdravnika.
Therefore, Pelzont should not be used in children and adolescents under 18 years of age. 
Zato se zdravila Pelzont ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
What Pelzont is and what it is used for What you need to know before you take Pelzont How to take Pelzont 
Kaj je zdravilo Pelzont in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Pelzont Kako jemati zdravilo Pelzont
Figure 2 Percentage of Patients with Moderate or Greater Flushing Symptoms Across Weeks 1-32 
Slika 2 Odstotek bolnikov z zmernimi ali izrazitejšimi simptomi zardevanja od 1. do 32. tedna
MARKETING AUTHORISATION NUMBER(S) EU/1/08/460/012 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/460/012
The safety of concomitant administration of nicotinic acid and laropiprant was assessed in dogs and rats. 
Varnost sočasne uporabe nikotinske kisline in laropipranta so ocenili pri psih in podganah.
• when you cannot control your cholesterol levels with a statin alone (class of cholesterol-lowering medicines working in the liver); 
• če holesterola ne morete obvladati samo s statinom (statini so skupina zdravil za zniževanje holesterola, ki delujejo v jetrih).
Effect on skeletal muscle 
Vpliv na skeletne mišice
• rapid or irregular heartbeat 
• hitro ali nepravilno bitje srca
▲ Pelzont  nicotinic acid (laropiprant withdrawn at Week 21) 
▲ Pelzont  nikotinska kislina (ukinitev laropipranta v 21. tednu)
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP). 
Imetnik dovoljenja za promet z zdravilom bo izvedel farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
In most people, at first there are no signs of cholesterol problems. 
Pri večini ljudi nenormalna raven holesterola sprva ne povzroča nobenih bolezenskih znakov.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure, indicating little relevance to human use. 
V predkliničnih študijah so učinke opazili samo pri izpostavljenosti, ki je močno presegala največjo izpostavljenost pri človeku, kar kaže na majhen pomen za uporabo pri ljudeh.
• you are taking simvastatin (a statin) or a medicine containing simvastatin and are Chinese. 
• če jemljete simvastatin (statin) ali zdravilo, ki vsebuje simvastatin, in ste Kitajec.
Uncommon: palpitations Rare: atrial fibrillation and other cardiac arrhythmias; tachycardia 
Redki: atrijska fibrilacija in druge srčne aritmije; tahikardija
Clinically important elevations of CK (≥ 10 X ULN) were seen in 0.3 % of the patients treated with Pelzont with or without a statin (see section 4.4). 
Klinično pomembno zvišanje CK (≥ 10 x ZNM) so opazili pri 0,3 % bolnikov, ki so dobivali zdravilo Pelzont s statinom ali brez njega (glejte poglavje 4.4).
Therefore, laropiprant is not an inducer or inhibitor of CYP3A4. 
Laropiprant torej ne inducira in ne zavira CYP3A4.
Average number of days per week with moderate or greater* flushing symptoms across weeks 1-24 
Povprečno število dni na teden z zmernimi ali izrazitejšimi* simptomi zardevanja od 1. do 24. tedna
In urine, the primary component is the acyl glucuronide conjugate (64 % of radioactivity) with smaller contributions from the parent compound (5 %). 
V urinu je glavna z zdravilom povezana snov acilglukuronidni konjugat (64 % radioaktivnosti), z manjšim prispevkom matične spojine (5 %).
The major component (73 % of radioactivity) in faeces is laropiprant (comprising unabsorbed active substance and/or hydrolysed glucuronic acid conjugate). 
Glavna snov (73 % radioaktivnosti) v blatu je laropiprant (obsega neabsorbirano zdravilo in/ali hidrolizirani konjugat z glukuronsko kislino).
During controlled clinical trials in healthy subjects, single doses of up to 900 mg laropiprant and multiple doses up to 450 mg once daily for 10 days were generally well tolerated. 
V kontroliranih kliničnih preskušanjih so zdravi preiskovanci večinoma dobro prenašali posamične odmerke do 900 mg laropipranta in večkratne odmerke do 450 mg enkrat na dan 10 dni.
Midazolam: Multiple doses of laropiprant 40 mg did not affect the pharmacokinetics of midazolam, a sensitive CYP3A4 substrate. 
Midazolam: Večkratni odmerki 40 mg laropipranta niso vplivali na farmakokinetiko midazolama, ki je občutljiv substrat CYP3A4.
In diabetic patients a median increase in HbA1c of 0.2 % was observed (where modification of hypoglycaemic therapy was allowed). 
Pri sladkornih bolnikih so opazili povečanje HbA1c (mediana vrednost) za 0,2 % (pri čemer je bila dovoljenja prilagoditev antidiabetičnega zdravljenja).
In an interim analysis of an ongoing clinical outcome study, an independent safety monitoring committee identified a higher than expected incidence of myopathy in Chinese patients taking Pelzont and simvastatin 40 mg. 
V vmesni analizi trenutno potekajoče preživetvene študije je neodvisen odbor za spremljanje varnosti odkril višjo pojavnost miopatije pri kitajskih bolnikih, ki so jemali zdravilo Pelzont in simvastatin 40 mg,
Pelzont is used in addition to diet and exercise in adult patients with primary hypercholesterolaemia or mixed dyslipidaemia: 
Zdravilo Pelzont se uporablja poleg diete in telesne vadbe pri odraslih bolnikih s primarno hiperholesterolemijo ali z mešano dislipidemijo:
Pelzont has not been studied in children and adolescents who are under 18 years of age. 
Zdravilo Pelzont ni raziskano pri otrocih in mladostnikih, mlajših od 18 let.
The Coronary Drug Project, a five year study completed in 1975, showed that nicotinic acid had a statistically significant benefit in decreasing nonfatal, recurrent myocardial infarctions (MI) in men 30 to 64 years old with a history of MI. 
Pet-letna študija Coronary Drug Project, ki se je končala leta 1975, je pokazala, da nikotinska kislina statistično značilno pripomore k zmanjšanju števila neusodnih ponovnih miokardnih infarktov (MI) pri moških od 30. do 64. leta starosti z anamnezo MI.
• If you take more than you should, talk to a doctor or pharmacist straight away. 
• Če vzamete več zdravila, kot bi smeli, se morate takoj posvetovati z zdravnikom ali s farmacevtom.
In a pool of four active- or placebo-controlled clinical trials (N=4,747, n=2,548 taking Pelzont), flushing was reported in 12.3 % of patients taking Pelzont. 
V štirih z učinkovino ali s placebom kontroliranih kliničnih preskušanjih (N = 4.747, n = 2.548 jih je jemalo zdravilo Pelzont) so o zardevanju poročali pri 12,3 % bolnikov, ki so jemali Pelzont.
• to raise levels of ‘good' cholesterol (HDL cholesterol) and apo A-I (a part of HDL). 
• zvišanje "dobrega" holesterola (HDL holesterola) in apo A-I (ki je del HDL).
Transaminase elevations were reversible upon discontinuation of therapy. 
Zvišanja transaminaz so bila po prenehanju uporabe zdravila reverzibilna.
Do not take Pelzont if any of the above apply to you. 
Ne vzemite zdravila Pelzont, če kaj od naštetega velja za vas.
Other medicines and Pelzont 
Druga zdravila in zdravilo Pelzont
As with other nicotinic acid medicinal products, caution should be used when Pelzont is used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive medicinal products such as nitrates, calcium channel blockers, or adrenergic blocking agents. 
Tako kot velja za druga zdravila z nikotinsko kislino, je tudi pri zdravilu Pelzont potrebna previdnost, če ga uporabljate pri bolnikih z nestabilno angino pektoris ali med akutno fazo MI, zlasti kadar takšni bolniki dobivajo tudi vazoaktivna zdravila, kot so nitrati, zaviralci kalcijevih kanalov ali adrenergični zaviralci.
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated. 
Kot monoterapija se lahko uporabi samo pri bolnikih, za katere zaviralci reduktaze HMG-CoA niso primerni ali jih ne prenašajo.
Pelzont should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. 
Zdravilo Pelzont morate previdno uporabljati pri bolnikih, ki uživajo velike količine alkohola in/ali imajo anamnezo bolezni jeter.
Laropiprant and its acyl glucuronide conjugate are the major circulating components in human plasma. 
Laropiprant in njegov acilglukuronidni konjugat sta pri človeku glavni v plazmi krožeči spojini.
Effect on glucose 
Vpliv na glukozo
• Take Pelzont with food. 
• Vzemite ga s hrano.
The effect on lipids was similar whether Pelzont was given as monotherapy or was added to ongoing statin therapy with or without ezetimibe. 
Učinek na lipide je bil podoben, naj je bilo zdravilo Pelzont uporabljeno v monoterapiji ali dodano že vpeljanemu statinskemu zdravljenju, z ezetimibom ali brez njega.
Caution should be exercised in patients with pre-disposing factors for rhabdomyolysis. 
Previdnost je potrebna pri bolnikh z že obstoječimi dejavniki za pojav rabdomiolize:
Effects of laropiprant on other medicinal products 
Vplivi laropipranta na druga zdravila
Supplements containing nicotinic acid: Vitamins or other nutritional supplements containing (≥ 50 mg/day) of nicotinic acid (or nicotinamide) have not been studied with Pelzont. 
Dodatki, ki vsebujejo nikotinsko kislino: Uporaba vitaminov in drugih prehranskih dopolnil, ki vsebujejo (≥ 50 mg/dan) nikotinsko kislino (ali nikotinamid) hkrati z zdravilom Pelzont ni raziskana.
If Pelzont is missed for less than 7 consecutive days, patients can resume therapy at the last administered dose. 
Če bolnik zdravila Pelzont ne vzame manj kot 7 dni zapored, ga lahko znova začne jemati v nazadnje uporabljanem odmerku.
Genetic and pharmacologic studies in animal models have provided evidence that PGD2, acting through DP1, one of the two receptors for PGD2, plays a key role in nicotinic acid-induced flushing. 
Z genetskimi in farmakološkimi študijami na živalskih modelih so dokazali, da je za zardevanje zaradi nikotinske kisline ključno delovanje PGD2, ki deluje preko DP1, ki je eden od dveh receptorjev za PGD2.
In interaction studies, laropiprant did not have clinically significant effects on the pharmacokinetics of the following medicinal products: simvastatin, warfarin, oral contraceptives, rosiglitazone and digoxin. 
V študijah medsebojnega delovanja zdravil laropiprant ni klinično pomembno vplival na farmakokinetiko naslednjih zdravil: simvastatina, varfarina, peroralnih kontraceptivov, roziglitazona in digoksina.
Other medicinal products: Co-administration of laropiprant 40 mg with midazolam increased the AUC0-∞ and Cmax of 1'-hydroxymidazolam, a midazolam metabolite, by 98 % and 59 %, respectively. 
Druga zdravila: Pri sočasni uporabi 40 mg laropipranta in midazolama sta se povečali AUC0-∞ in Cmax midazolamovega presnovka 1'-hidroksimidazolama za 98 % oz. 59 %.
In vitro studies have shown that the acyl glucuronide conjugate of laropiprant had at least a 65-fold reduced affinity for DP1 as compared to laropiprant; thus, it is not expected to contribute to the overall DP1 activity of laropiprant. 
Po študijah in vitro ima acilglukuronidni konjugat laropipranta vsaj 65-krat manjšo afiniteto za DP1 kot laropiprant, zato ni pričakovati, da bi prispeval k celotni DP1-aktivnosti laropipranta.
Flushing is the most common adverse reaction of Pelzont. 
Zardevanje je najpogostejši neželeni učinek zdravila Pelzont.
Nicotinic acid is less than 20 % bound to serum proteins. 
Manj kot 20 % nikotinske kisline se veže na beljakovine v serumu.
Laropiprant is not expected to inhibit the production of prostaglandins. 
Ni pričakovati, da bi laropiprant zaviral nastajanje prostaglandinov.
• clopidogrel and acetylsalicylic acid (ASA), medicines to help prevent harmful blood clots. 
• klopidogrel in acetilsalicilno kislino, ki sta zdravili za preprečevanje škodljivih krvnih strdkov.
• you or close family members have a hereditary muscle disorder, or you have ever had muscle problems during treatment with cholesterol-lowering medicines called “statins” or fibrates. 
• če imate vi ali vaš ožji družinski član dedno bolezen mišic, ali ste kdaj tekom zdravljenja z zdravili za zniževanje holesterola, imenovanimi statini ali fibrati, imeli težave z mišicami.
1'-hydroxymidazolam is metabolised predominantly by uridine diphosphate-glucuronosyltransferases (UGT) 2B4 and 2B7. 
1'-hidroksimidazolam se presnavlja predvsem z uridindifosfat-glukuronoziltransferazama (UGT) 2B4 in 2B7.
If you forget to take Pelzont 
Če ste pozabili vzeti zdravilo Pelzont
If you stop taking Pelzont Do not stop taking Pelzont without talking to your doctor. 
Ne nehajte jemati zdravila Pelzont, ne da bi se posvetovali s svojim zdravnikom.
HDL is hypothesised to participate in the transport of cholesterol from tissues back to the liver, to suppress vascular inflammation associated with atherosclerosis, and to have anti-oxidative and anti-thrombotic effects. 
HDL domnevno sodeluje v prenosu holesterola iz tkiv nazaj v jetra, zavira z aterosklerozo povezano žilno vnetje ter deluje antioksidativno in antitrombotično.
Like other nicotinic acid medicinal products, Pelzont is contraindicated in patients with significant or unexplained hepatic dysfunction. 
Tako kot druga zdravila z nikotinsko kislino je tudi zdravilo Pelzont kontraindicirano pri bolnikih s pomembno ali nepojasnjeno motnjo delovanja jeter.
• to lower your ‘bad' cholesterol level. 
• znižanje "slabega" holesterola.
Patients with combined mixed dyslipidaemia have high blood levels of ‘bad' LDL cholesterol and triglycerides (a type of fat), and low levels of ‘good' HDL cholesterol. 
Bolniki s kombinirano mešano dislipidemijo imajo v krvi visoke vrednosti "slabega" LDL holesterola in trigliceridov (vrsta maščobe) in nizke vrednosti "dobrega" HDL holesterola.
• you have unexplained muscle pain, muscle tenderness, or muscle weakness. 
• če imate nepojasnjene bolečine v mišicah, občutljive ali šibke mišice.
The reduction in flushing symptoms (assessed by patient questionnaires) was correlated with a reduction in nicotinic acid-induced vasodilatation (assessed by measurements of skin blood flow). 
Zmanjšanje simptomov zardevanja (ocenjeno z vprašalniki za bolnike) je bilo povezano z zmanjšanjem vazodilatacije zaradi nikotinske kisline (vazodilatacijo so ugotavljali z merjenjem pretoka krvi skozi kožo).
Nicotinic acid causes a relative shift in the distribution of LDL subclasses from small, dense (most atherogenic) LDL particles to larger LDL particles. 
Farmakodinamični učinki Nikotinska kislina povzroči relativen premik porazdelitve podskupin LDL od majhnih, gostih (najbolj aterogenih) delcev LDL proti večjim delcem LDL.
• flushing (which usually includes redness of the skin, feeling warm, itching, or tingling, particularly in the head, neck, chest and upper back). 
• zardevanje (ki ponavadi vključuje pordelost kože, občutek toplote, srbenje ali mravljinčenje, še zlasti v predelu glave, vratu, prsi in zgornjega dela hrbta).
It is not known if Pelzont will pass into your breast milk. 
Ni znano, ali zdravilo Pelzont prehaja v materino mleko.
Nicotinic acid-induced flushing is mediated primarily by release of prostaglandin D2 (PGD2) in the skin. 
Zardevanje zaradi nikotinske kisline je predvsem posledica sproščanja prostaglandina D2 (PGD2) v koži.
• When new information is received that may impact on the current Safety Specification, 
• po prejemu novih informacij, ki lahko vplivajo na trenutne specifikacije varnosti zdravila, načrt farmakovigilance ali na dejavnosti za zmanjšanje tveganja,
When driving vehicles or operating machines, it should be taken into account that dizziness has been reported (see section 4.8). 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Pri vožnji oz. upravljanju s stroji je treba upoštevati, da so poročali o omotici (glejte poglavje 4.8).
• The active substances are nicotinic acid and laropiprant. 
• Zdravilni učinkovini sta nikotinska kislina in laropiprant.
Common: elevations in ALT and/or AST (consecutive, ≥ 3 X ULN), fasting glucose (see below) Uncommon: elevations in CK (≥ 10 X ULN), LDH, uric acid (see 
Pogosti: zvišanje ALT in/ali AST (zaporedno, ≥ 3 x ZMN), glukoze na tešče (glejte spodaj) Občasni: zvišanje CK (≥ 10 x ZMN), LDH, sečne kisline (glejte spodaj)
Therefore, treatment with acetylsalicylic acid to alleviate flushing symptoms is not necessary (see section 5.1). 
Zato za ublažitev simptomov zardevanja ni treba uporabljati acetilsalicilne kisline (glejte poglavje 5.1).
• swelling of the fingers, toes or ankles 
• oteklost prstov na rokah in nogah ali gležnjev
• medicines used to lower cholesterol called ‘statins'. 
• zdravila za zniževanje holesterola, ki jih imenujemo "statini".
Additional explanations that do not invoke plasma FFA reduction as the central driver of lipid profile modification include nicotinic acid-mediated inhibition of de novo lipogenesis or esterification of fatty acids into TG in the liver. 
Dodatne razlage, ki ne zajemajo znižanja PMK v plazmi kot glavnega gonila sprememb sestave lipidov, vključujejo z nikotinsko kislino posredovano zavrtje de novo lipogeneze ali esterifikacijo maščobnih kislin v trigliceride v jetrih.
Very few medicinal products are known to be metabolised predominantly by UGT2B4 or UGT2B7. 
Za zelo malo zdravil je znano, da se presnavljajo pretežno z UGT2B4 ali UGT2B7.
Laropiprant is not a substrate of human P-gp, and therefore other inhibitors of CYP3A4 and/or P-gp are also not expected to have a clinically meaningful impact on the pharmacokinetics of laropiprant. 
Laropiprant ni substrat humanega P-gp, zato ni pričakovati, da bi drugi zaviralci CYP3A4 in/ali P-gp klinično pomembno vplivali na farmakokinetiko laropipranta.
Nicotinic acid was not carcinogenic in mice when administered for the duration of their life. 
Nikotinska kislina ni bila kancerogena pri miših, ki so jo dobivale vse življenje.
At higher doses or higher rates of absorption, the NAD pathway is saturable, and an increasing fraction of the oral dose reaches the bloodstream unchanged as nicotinic acid. 
Med uporabo večjih odmerkov oz. pri večji absorpciji pa se NAD-pot nasiti in vse večji delež peroralnega odmerka pride v krvni obtok kot nespremenjena nikotinska kislina.
The placebo-adjusted LDL-C, HDL-C and TG responses appeared greater among women compared to men and appeared greater among elderly patients (≥ 65 years) compared to younger patients (< 65 years). 
S placebom korigirani odzivi hLDL, hHDL in trigliceridov so bili pri ženskah večji kot pri moških in pri starejših bolnikih (≥ 65 let) večji kot pri mlajših (< 65 let).
• you have ever had liver disease, jaundice (a liver disorder causing yellowing of the skin and whites of the eyes), or hepatobiliary (liver and bile duct) disease. 
• če ste kdaj imeli bolezen jeter, zlatenico (bolezen jeter, ki povzroči porumenitev kože in očesne beločnice) ali bolezni jeter in žolčnih vodov.
LDL cholesterol is often called ‘bad' cholesterol because it can build up in the walls of your arteries and form plaque. 
LDL holesterol pogosto imenujemo "slabi" holesterol, ker se lahko kopiči v stenah arterij in tako povzroči nastanek leh.
If you get dizzy, you should avoid driving or operating machines after taking Pelzont. 
Če postanete omotični, se med jemanjem zdravila Pelzont izogibajte vožnji ali upravljanju strojev.
If you take more Pelzont than you should 
Če ste vzeli večji odmerek zdravila Pelzont, kot bi smeli
After 4 weeks, your doctor may raise your dose of Pelzont to two tablets a day. 
Po 4 tednih vam zdravnik lahko odmerek poveča na dve tableti zdravila Pelzont na dan.
In order for your medicine to work as intended, do not split, break, crush, or chew the tablet before you swallow it. 
Da bo zdravilo delovalo tako kot mora, tablet ne razpolavljajte, ne lomite, ne drobite in ne grizite, preden jih pogoltnete.
Common: erythema; pruritus; rash; urticaria Uncommon: dry skin; macular rash Rare: acanthosis nigricans; hyperpigmentation; sweating (night or cold sweat) 
Pogosti: eritem; pruritus; izpuščaj; urtikarija Občasni: suha koža; makularni izpuščaj Redki: acanthosis nigricans; hiperpigmentacija; znojenje (nočno znojenje ali hladen znoj)